

IFMP WORKSHOP IN IONIAN UNIVERSITY, CORFU, GREECE
Friday 10/11/2017 8:30

PARTICLE THERAPY CRITICAL ISSUES AND CHALLENGES

Patrick Ledu, PhD

INP Lyon and IEEE

This talk will illustrate this comment from Prof. Wolfgang Enghardt, one of the pioneer in particle therapy:

“Particle therapy units should be equipped with the most advanced imaging and motion tracking devices available and Not with the technologies of the last century”

. The topics presented are:



- Machine and beam production
- Patient monitoring in real time
- Proton and ion CT developments

Particle therapy Critical issues and Challenges



P. Le Dû

patrickledu@me.com




*Conclusion from a pioner
Prof. W. Enghardt Oncoray, Dresden*


**Strongly
Approve**

***Particle thearapy units should
be equipped with the most
advanced imaging and motion
tracking devices available***

***And Not with the technology of the
last century***



Particle therapy environment



- Machine
- Beam delivery
- Photon detectors
- CT imaging
- Motion sensor

*Courtesy
Katia Parodi*

Treating Cancer

■ Radiotherapy X

- Local irradiation \rightarrow 100 Gy = 90 % of sterilization
- Frequent treatment (2/3 of cases).
- Allow good quality of life and tolerance
- non invasive, itinerant and without important physical effects.
- Cheap (< 10%) of the cancer budget (France)
- Essentially X rays (Linear accelerators) & photons (curietherapy)
- **Efficient treatment but ...**

Estimated absolute yearly rate (%) of 2nd cancer after radiotherapy

| <i>Tumor site</i> | <i>X-rays</i> | <i>IMXT</i> | <i>Protons</i> |
|----------------------------------|---------------|-------------|----------------|
| <i>Oesoph. & stomach</i> | 0.15 | 0.11 | 0.00 |
| <i>Colon</i> | 0.15 | 0.07 | 0.00 |
| <i>Breast</i> | 0.00 | 0.00 | 0.00 |
| <i>Lung</i> | 0.07 | 0.07 | 0.01 |
| <i>Thyroid</i> | 0.18 | 0.06 | 0.00 |
| <i>Bone & soft tissue</i> | 0.03 | 0.02 | 0.01 |
| <i>Leukemia</i> | 0.07 | 0.05 | 0.03 |
| <i>All</i> | 0.75 | 0.43 | 0.05 |
| <i>Compared to X-rays</i> | 1 | 0.6 | 0.07 |


Particle therapy: The Context

- *Why Radiotherapy X is NOT 100 % efficient?*
 - Complication < 5 %
 - Tolerance of saine tissue is the limiting factor
 - **Close to Organ at Risk**
 - Failures due to radioresistant tumors!
 - Second cancer 30 years after Radio Therapy (from recent statistics)
 - **Adult : 1.1**
 - **Chidren : 6**

→ Particle therapy
around 15% of the cases

Hadrontherapy principle (C ion)


Absorbed dose



Electron : most of the energy released in first cm

Photon : Large energy loss all over the path (X rays therapy)

C ions : heavy charged particle : most of the energy lost at the end of path (Braggs peak)



Particle therapy workflow


- Step 1 → Treatment planning after CT scan
 - Dose to be distributed
 - MC simulation
 - Give information to the machine



- 10-20 fractions (tumour irradiation)


- Step 3 → verification using CT scan

Overdosage in normal tissue



What are the critical issues & challenges?

- This is NOT a 'simple target' but a human body
 - Treatment and quality assurance techniques of conventional radiotherapy not adequate for particle therapy
 - A complex procedure for the 'treatment planning'
- How to be sure that the dose is delivered at the right place (tumour)?
 - Particle beam are error sensitive
 - Displaced organ & overdose
 - Moving organ in some case




*What is the dose deposited?
How to verify the treatment?*

The two 'simultaneous' challenges

- Reducing error means → **Real Time imaging**
 - 3D in vivo dosimetry and tomography
 - *Use fragments of beam projectile reactions in the biological matter emerging from the tumor target volume*
- Verification using Computed Tomography/Radiography:
 - CT imaging in charged Particle therapy is needed for:
 - Target volume definition (anatomical boundaries with additional information from multimodality imaging (CT/MRI/PET studies))
 - Dose and range calculation
 - Patient alignment verification



But today these process are made at different moment and place

In-beam nuclear method principle for 'in vivo' dosimetry



Balance of promptly emitted particles outside the target:

| | | |
|----------------------|-------------------|--------------------|
| Incident protons: | 1.0 | ($\sim 10^{10}$) |
| γ -rays: | 0.3 | ($3 \cdot 10^9$) |
| Neutrons: | 0.09 | ($9 \cdot 10^8$) |
| Protons: | 0.001 | ($1 \cdot 10^7$) |
| α -particles: | $2 \cdot 10^{-5}$ | ($2 \cdot 10^5$) |




■ However the photon energy different from standard medical (Anger) SPECT camera


Relation between dose and β^+ activities¹²

Single photon: in vivo Compton Camera

γ -rays MC simulation




(A.Muller, TU Dresden)




- Required devices:
 - Hodoscope (x, y, t)
 - Scatterer (x, y, E)
 - Absorber (x, y, z, E, t)



Scintillating-fibre
Hodoscope + MA PMT
Ray et al. IPN Lyon




C.Llosa, IFIC
IFMP_CORFU_17




CZT-strip+LYSO-block Detector
F.Fiedler et al. Dresden

Example of Single photon: in vivo SPECT


single slit




multi slit



CZT-strip+LSO-block Detector






CZT0A, channel 10 CZT0Ach10
 Entries: 600-1
 Mean: 218.3
 RMS: 138.9

^{22}Na $\frac{\Delta E}{E} \approx 3\%$

ADC channel



BaF2 or NaI

Pb Shielding


Pb collimator
20 cm thick
2 mm slit

PMMA target

beam


~ 60 cm


Scintillating-fibre Hodoscope



2x128 (1x1mm²)

Timing ASIC





Le Foulher et al. 2010
IPN Lyon

Krimmer, De Rydt
IPN Lyon



$\sigma_t \sim 1\text{ns} @ 10^8 \text{ s}^{-1}$

T. Kormoll, et al.,
NIM A626 (2011) 114,
IEEE NSS-MIC, 2011, pp. 3484

Present examples: in beam PET



In-beam PET scanner at ^{12}C -therapy unit at GSI



^1H -therapy at the National Cancer Center, Kashiwa, Japan

- Large beam background
- No Real time capability
- Low signal to noise ratio

Positron Emission Tomograph ...some Hardware

In-beam: GSI Darmstadt *Off-line: MGH Boston, HIT Heidelberg*




more...

- *HIMAC, Chiba*
- *NCC, Kashiwa*
- *HIBMC, Hyogo*
- *MDACC, Houston*
- *Univ. of Florida*

- ☺ *In-vivo range measurements*
- ☹ *In-vivo dosimetry & real-time image guidance*
- *Ongoing developments (TOF-PET, PET+CT)*
reduce unfavorable in-beam random coincidences/background (by 20-30%)


Mature technology

In vivo PET recent developments




NeuroPET/CT in proton Tx room at MGH, ready to scan

MGH



Courtesy T. Yamaya, NIRS Japan
Presented at IEEE MIC 2014



TU-Delft group dual-head prototype

Philips dSiPM and LYSO arrays


Another dream The Proton CT



Why particle CT ?

- *The role of CT imaging in charged Particle therapy is needed for:*
 - *Target volume definition (anatomical boundaries with additional information from fused MRI and PET studies)*
 - *Dose and range calculation*
 - *Patient alignment verification*


The protons go through the patient
Higher energy, **small dose**



Basics of particle imaging

- *The particle (proton/ion) go through the patient at high energy*
- *Advantages:*
 - *Decrease the uncertainties → better dose accuracy*
 - *Reduce the dose delivered to the patient*
- *Challenge → the data reconstruction*
 - *correctly reconstruct the path of the proton*

Proton CT:
1) replaces X-ray absorption with proton energy loss
2) reconstruct mass density distribution instead of electron distribution



Radiograph of a phantom
Uwe Schneider PhD thesis
(1978, PSI)

A tribute to G.Charpak

X ray & CT after each fraction ?

- X ray is **agressive** --> see table below about estimated absolute rate of (%) of 2nd cancer
 - 30-50 mGy/scan
 - 30 fraction daily --> Total : 0,6 -3 Gy


| <i>Tumor site</i> | <i>X-rays</i> | <i>IMXT</i> | <i>Protons</i> |
|-------------------------------|---------------|-------------|----------------|
| <i>Oesoph. & stomach</i> | 0.15 | 0.11 | 0.00 |
| <i>Colon</i> | 0.15 | 0.07 | 0.00 |
| <i>Breast</i> | 0.00 | 0.00 | 0.00 |
| <i>Lung</i> | 0.07 | 0.07 | 0.01 |
| <i>Thyroid</i> | 0.18 | 0.06 | 0.00 |
| <i>Bone & soft tissue</i> | 0.03 | 0.02 | 0.01 |
| <i>Leukemia</i> | 0.07 | 0.05 | 0.03 |
| <i>All</i> | 0.75 | 0.43 | 0.05 |
| <i>Compared to X-rays</i> | 1 | 0.6 | 0.07 |

The Basics Ingredients

- Beam
 - Measurement (position and direction) particle per particle
- Photon detectors
 - In beam selection of
 - single photon → compton camera (SPECT)
 - two photons → in Beam TOF-PET
- Proton (ion) CT
 - Measure the energy (position, energy and time) of the diffracted particle in an imaging calorimeter
- The Global aspect!
 - Event by event selection particle like in a nuclear & HEP physics experiment.
 - Deatimeless electronics
 - Real time acquisition and reconstruction

Need all HEP modern instrumentation tools & technique


Schematic block diagram of an integrated concept of radiography / therapy system



- Identify tracks and energy deposition of individual protons
- Scintillators for trigger to read-out detectors
- Tracking detectors for 3D tracks
- Sampling Calorimeter for energy determination
- High rate integrated DAQ

Nov 17

IFMP_CORFU_17



Present examples : PCT

- Different prototypes are proposed based on the same "philosophy" (Reinhard Schulte et Al.)
 - BNL, Santa Cruz, Loma Linda, Stony Brook layout (2003)







Fig. 1. The Proton Range Radiography setup.

AQUA-CNAO
Scint/MPPC/GEM







NIU/FNAL
Scint/WLS+SiPM
GPU farm



- Ion Transmission Imaging
→ See talk from B.Voss

Primary-Ion Radiography / Tomography



Transmission ion imaging prior to or in-between RT is feasible

Final Conclusions




*There is a lot to do
Particularly
for students*

*References
Proceedings
of NSS-MIC
conferences*

Transaction on Nuclear Sciences (TNS)

<http://www.nss-mic.org/2016/NSSMain.asp>



Thanks to

- D. Townsend (U. Singuapor)
- W. Enhardt (Dresden)
- H. Frisch (U. Chicago)
- P. Lecoq (CERN)
- R. Lecomte (Sherbrook)
- W. Moses (LBL)
- J. Karp (U. Penn)
- J. Varela (LIP)
- S. Ritt (PSI)
- S. Majewski (WVU)
- K. Parodi (HIT)
- Pr. J.N. Talbot (Hopital Tenon - Paris)
- Pr. J.P. Gerard (Nice)
- ... and many others



*Thank you
for your attention*